Azalea Therapeutics develops precision genomic medicines by engineering T cells directly inside the body for cancer immunotherapy. The company utilizes Envelope Delivery Vehicles (EDVs) to selectively deliver genome editing cargo to T cells. This approach aims to create faster, more accessible, and potent cell therapies by avoiding complex ex vivo manufacturing.
Funding
Funding not disclosed
Founders
Product
Problem
Current autologous CAR‑T cell therapies require ex vivo extraction, genetic modification, and expansion of patient T cells, a process that is labor‑intensive, expensive, and limited to specialized manufacturing sites, restricting patient access and slowing treatment timelines.
Solution
Azalea Therapeutics delivers precision genome‑editing cargo directly to circulating T cells using engineered Envelope Delivery Vehicles (EDVs). The non‑viral particles are surface‑engineered to bind T‑cell–specific receptors, enabling selective uptake in vivo. Once internalized, CRISPR‑Cas nucleases insert a CAR construct into the TRAC locus, creating functional CAR‑T cells without the need for cell harvesting or ex vivo culture. A single intravenous infusion can generate a therapeutic dose of engineered T cells, reducing manufacturing complexity, cost, and time to treatment. The platform is designed to be modular, allowing rapid re‑programming of the payload for different tumor antigens and disease indications. Preclinical studies have demonstrated robust, durable CAR‑T cell generation and tumor regression after a single dose.
Target Audience
The primary customers are pharmaceutical and biotech companies developing oncology cell therapies, as well as academic research groups seeking an in vivo platform for T‑cell engineering. Clinical oncology programs looking to accelerate CAR‑T access for patients also constitute a key market segment.
Features
- Envelope Delivery Vehicles (EDVs) composed of a minimal biological particle optimized for high‑efficiency, non‑viral delivery of CRISPR‑Cas payloads to human T cells.
- Surface ligand display that confers selective binding to CD3/CD4/CD8 markers, ensuring cell‑type specificity and minimizing off‑target transduction.
- Precise genomic integration at the TRAC locus using homology‑directed repair, yielding uniform CAR expression and reduced tonic signaling.
- Single‑dose intravenous administration that eliminates ex vivo cell processing, cryopreservation, and logistics.
- Modular cargo architecture supporting CRISPR nucleases, base editors, or transgenes for a broad range of oncology targets.
- Scalable GMP‑compatible EDV production pipeline leveraging cell‑free assembly to support commercial manufacturing volumes.
- Comprehensive preclinical safety package demonstrating transient expression of editing components and absence of integration‑related genotoxicity.